GLUTAMATE MODULATION PLATFORM
Our glutamate modulation platform is comprised of two product candidates: troriluzole (BHV-4157) and BHV-5000/5500. These work in the body to balance the glutamate system via two distinct mechanisms: glutamate transporter modulation (troriluzole) and N-methyl-D-aspartate, or NMDA, glutamate receptor antagonism (BHV-5000/5500). Troriluzole is currently in late-stage development for spinocerebellar ataxia (SCA) and obsessive compulsive disorder (OCD).
GLUTAMATE PLATFORM PRODUCT CANDIDATES
NCE prodrug of riluzole
Obsessive-Compulsive Disorder (OCD)
Spinocerebellar Ataxia (SCA)